The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000615381
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
17/04/2026
Date registered
Help: Date registered
19/05/2026
Date last updated
Help: Date last updated
19/11/2026
Date data sharing statement initially provided
Help: Data sharing statement date
19/05/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A trial to assess the safety, tolerability and efficacy of RES-010 in overweight and obese adults without obesity-related comorbidities.
Scientific title
A Phase 1b, Randomized, Double-Blinded, Placebo Controlled, MAD Study Evaluating the safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of RES-010 in Overweight and Obese Adults without Obesity-Related Comorbidities.
Additional trial identifiers [1] 316803 0
RES-010-002
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Obesity (Mild) 341212 0
Overweight 341213 0
Condition category
Condition code
Diet and Nutrition 337299 337299 0 0
Obesity

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This study aims to find out if the study drug, RES-010, is safe and tolerable, and if RES-010 can help with weight loss.

This is a dose escalation study, which means the first group enrolled will receive the lowest dose and once it is considered to be safe, the next group will be enrolled and will receive the next higher dose. Dose escalation will only proceed following review of information/results from the dosing of previous participants, including the results of blood tests and other assessments. This decision will be made by the Principal Investigator and the Sponsor if there is confirmation that it is safe to continue with the next higher dose in the next group. The study can be stopped at any time based on evaluation of the side effects of the study drug. The maximum dose of RES-010 for Cohorts 2 and 3 has not yet been determined.

This study will enrol up to 36 overweight or mildly obese patients randomly assigned to either RES-010 or placebo treatment groups, with participants having a 3 in 4 chance of receiving the study drug RES-010. The study will be conducted in up to three groups (called cohorts), with 12 participants in each cohort.

The study treatment groups (cohorts) include:
1. Cohort 1: subcutaneous injection in abdomen (injection under the skin) with a starting dose of 45mg of RES-010 for 12 weeks, administered as a single injection, every dosing (once per week).
2. Cohort 2: subcutaneous injection in abdomen with a next higher dose of RES-010 for 12 weeks, administered as a single injection, every dosing (once per week). The planned maximum dose for this cohort is 60 mg of RES-010 for 12 weeks, administered as a single injection, every dosing (once per week).
3. Cohort 3 (Optional): subcutaneous injection in abdomen with an additional higher or lower dose of RES-010 for 12 weeks, administered as a single injection, every dosing (once per week). The planned maximum dose for this cohort is 75 mg of RES-010 for 12 weeks, administered as a single injection, every dosing (once per week).

The planned multiple ascending dose (MAD) levels are 45 mg for Cohort 1, 60 mg for Cohort 2, and 75 mg for Cohort 3. The maximum dose in the study will not exceed 75 mg. Dose escalation and final confirmation of the dose for Cohorts 2 and 3 will be based on review of emerging safety and tolerability data from the previous cohort(s), together with available Pharmacokinetics (PK) and Pharmacodynamic (PD) data, where applicable. If escalation is not supported, a lower dose may be selected or escalation may be stopped, following Sponsor/Scientific Review Committee (SRC) review.

The subcutaneous injection site/location on abdomen will be closely monitored after study treatment administration in addition to safety assessments (including but not limited to Vital signs measured, Electrocardiogram (ECG), safety blood tests).
Intervention code [1] 333545 0
Treatment: Drugs
Description of the comparator or control
This study is placebo controlled.
One in 4 participants will be randomly assigned to receive placebo treatment.
The study treatment groups (cohorts) include placebo dosing:
1. Cohort 1: subcutaneous injection in abdomen (injection under the skin) with placebo (saline) for 12 weeks, administered as a single injection, every dosing (once per week).
2. Cohort 2: subcutaneous injection in abdomen with placebo (saline) for 12 weeks, administered as a single injection, every dosing (once per week).
3. Cohort 3 (Optional): subcutaneous injection in abdomen with placebo (saline) for 12 weeks, administered as a single injection, every dosing (once per week).
Control group
Placebo

Outcomes
Primary outcome [1] 344818 0
Assess safety of multiple ascending doses of RES-010 in healthy overweight and moderately obese adults without obesity-related comorbidities. Safety and tolerability will be assessed as a composite primary outcome.
Timepoint [1] 344818 0
Physical Examination assessment completed From Baseline, including Weekly Visits until End of Treatment at Day 79, and at the End of Study visit at Day 113, and Optional Safety follow-up visit or last clinic visit. Electrocardiogram (ECG) performed Pre-dose and 2 hours post-dose on study treatment days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78) and on Day 113 and Optional Safety follow-up visit or last clinic visit. Vital Sign measurements performed Pre-dose and 2 hours post-dose on Day 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and once at Screening visit, Day 2, 9, 23 and 113 and Optional Safety follow-up visit or last clinic visit. Clinical laboratory blood samples and urine samples will be collected once on Days 1, 2, 3, 8, 9, 15, 16, 23, 29, 30, 36, 37, 43, 44, 51, 57, 58, 64, 65, 71, 72, 79, 113 and Optional Safety Follow-up visit.
Secondary outcome [1] 459411 0
To characterize the pharmacokinetics (PK) of multiple ascending doses of RES-010 in healthy overweight and moderately obese adults without obesity-related comorbidities. Blood and Urine PK parameters assessed a composite secondary outcome.
Timepoint [1] 459411 0
PK Blood samples collected at Baseline (Day 1), Day 22, Day 50 and Day 78 at multiple time points including Pre-dose, 30 minutes post-dose, and 1, 2, 4 and 8 hours post-dose. PK Blood samples collected once on Days 2, 3, 8, 9, 15, 16, 23, 29, 30, 36, 37, 43, 44, 51, 57, 58, 64, 65, 71, 72, 79, 113. Urine PK samples collected at Baseline (Day 1), Day 22, Day 50 and Day 78 at pre-dose (up to 2 hours before study dose) and from 0 to 24 hours post-dose (all urine collections for 24 hours).

Eligibility
Key inclusion criteria
1. Willing and able to sign an Informed Consent Form (ICF).
2. Males and females 18 to 55 years, inclusive, at Screening.
3. Overweight or moderately obese participants (Body Mass Index (BMI) of 27.5 to 34.9 kg/m² inclusive) without obesity-related comorbidities at Screening.
4. Body Mass Index (BMI) category for cohort balance: Participants will be enrolled to achieve a target of 4 to 8 overweight participants and 4 obese participants within each cohort.
For this purpose:
a. Overweight will be classified as: Body Mass Index (BMI) of 27.5 to 29.9 kg/m² at Screening.
b. Obese (Class I) will be classified as: Body Mass Index (BMI) of 30.0 to 34.9 kg/m² at Screening.
5. Body Weight of 50.0 kg or more at Screening.
6. Participants must agree to use highly effective contraception such as:
a. Male participants, if not surgically sterilized or have partners of the same sex, must agree to use highly effective contraception and not plan a pregnancy or donate sperm from Day 1 until 90 days after the last study visit. Highly effective contraception for a male participant (and his female partner, if she is of
childbearing potential) is defined as using hormonal contraceptives or an intrauterine device combined with at least 1 of the following forms of
contraception: a diaphragm, a cervical cap, or a condom. Total abstinence from heterosexual intercourse up to 90 days after the last study visit, in accordance with the usual lifestyle of the participant, is also acceptable.
b. Female participants: Female participants of childbearing potential who have a fertile male sexual partners must agree to use highly effective contraception and not to undergo assisted reproductive procedures, including in vitro fertilisation (IVF), oocyte retrieval/collection, or oocyte donation, from Day 1 until 90 days after. Highly effective contraception is defined as using hormonal contraceptives or an intrauterine device combined with at least 1 of the following forms of contraception: a diaphragm, a cervical cap, or a condom. Total abstinence from heterosexual intercourse, in accordance with the usual lifestyle of the participant, is also acceptable.
7. A resting heart rate between 60 and 100 beats per minute after 5 minutes resting in a supine position.
8. The mean value of triplicate measurements of blood pressure at Screening, after resting for 5 minutes in a supine position, must be within the following ranges (unless deemed not clinically significant by the Investigator):
a) Systolic blood pressure from 90 to 160 mmHg, inclusive.
b) Diastolic blood pressure from 45 to 100 mmHg, inclusive.
9. All prescribed medication must have been/be stopped at least 21 days prior to Day 1, with the exception of hormonal contraceptives, and in the medical opinion of the Investigator would not adversely affect the participant.
10. Willingness to refrain from any other organized body weight reduction program (exercise programs or dietary modifications) from Screening until at least 4 weeks after the last dose of study drug, with the exception of MyFitnessPal which will be used in this study.
11. Any weight reduction medication within 4 weeks prior to screening until at least 4 weeks after the last dose of study drug.
12. Willingness to not initiate a new structured exercise program or substantially change their habitual activity while on the study.
13. All over-the-counter medication, vitamin preparations and other food supplements, or herbal medications (such as St. John’s wort) must have been/be stopped at least 14 days prior to Day 1, with the exception of acetaminophen.
14. Ability and willingness to abstain from alcohol from 48 hours prior to Screening, study dosing visits and end of study/early termination visit.
15. Ability and willingness to abstain from methylxanthine-containing beverages or food (coffee, tea, cola, chocolate, and energy drinks) for 48 hours immediately prior to Screening, study dosing visits and End of Study or Early Termination visit.
16. Ability and willingness to abstain from all tobacco and nicotine products from 48 hours prior to Day 1 until Day 79.
17. Good physical and mental health based on medical history, physical examination, clinical laboratory test results, electrocardiogram and vital signs.
18. Participants should have and be able to use a Smart phone, iPad, or laptop.
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Any findings in the medical examination (including blood pressure, heart rate, or electrocardiogram) deviating from normal and assessed as clinically relevant by the Investigator.
2. Any immune related sensitivity, history of severe allergy or hypersensitivity or ongoing clinically important allergy or hypersensitivity, as judged by the Investigator or history of hypersensitivity to drugs with a similar chemical structure or class to RES-010.
3. Any vaccination received within 30 days before Screening.
4. Relevant hepatic parameters exceeding alanine transaminase or aspartate transferase greater than 1.5 times upper limit of normal, total bilirubin greater than upper normal limit (exclusion of Gilbert’s disease), alkaline phosphatase greater than 1.3 times the upper normal limit at Screening or Day minus 1.
5. Thyroid stimulating hormone levels outside normal limits of the clinical laboratory’s reference range at Screening.
6. Abnormal amylase levels or chronic pancreatic illness at Screening.
7. Participants with clinical or biochemical (International Normalized Ratio greater than 1.2 or platelet count less than the lower limit of normal evidence of hepatic decompensation at Screening or on Day 1.
8. Previous participation in the current study.
9. Known allergy to local anaesthetics.
10. Employee of any organization associated with this study.
11. History of clinically relevant drug and/or food allergies.
12. Any previous weight reduction surgery, clinically significant body weight change 90 days prior to Day 1, or current (or within the last 3 months) participation in organized body weight reduction program, with the exception of MyFitnessPal which will be used in this study.
13. Use of tobacco products, vaping or nicotine products (such as patches, gum) within 30 days prior to Day 1.
14. History of alcohol abuse or drug addiction (including drugs such as cannabis and cannabis products) within the past 2 years.
15. Positive drug and/or alcohol screen (opiates, methadone, cocaine, amphetamines [including ecstasy], cannabinoids, barbiturates, benzodiazepines, gamma-hydroxybutyric acid (GHB), tricyclic antidepressants, and alcohol) at Screening and Day 1.
16. History of alcohol consumption of no more than 10 standard drinks per week and no more than 4 standard drinks on any one day, within 3 months prior to Screening.
17. Positive screen for hepatitis B surface antigen (HBsAg), anti–hepatitis B core antibody (HBcAb), hepatitis C virus (HCV) antibodies, or Human Immunodeficiency Virus (HIV) 1 and 2 antibodies.
18. Received active investigational product for any investigational study within 30 days prior to Day 1 or a weight loss investigational study within the last 6 months. Participation in 4 other investigational studies in the 12 months prior to Day 1.
19. Donation or loss of more than 450 mL of blood within 60 days prior to Day 1, donation, or loss of more than 1.5 litres of blood (for male participants) or more than 1.0 litres of blood (for female participants) in the 10 months prior to Day 1 in the current study.
20. Significant and/or acute illness within 5 days prior to Day 1 that may impact safety assessments, in the opinion of the Investigator.
21. Poor venous access.
22. A mean corrected QT interval using Fridericia’s formula interval greater than 450 milliseconds (for males) and greater than 470 milliseconds (for females) at Screening. If the mean FQT interval using Fridericia’s formula exceeds the limits above, one additional triplicate Electrocardiogram (ECG) may be performed. If this triplicate also gives an abnormal result, the participant should be excluded from the study.
23. Estimated glomerular filtration rate rate by Chronic Kidney Disease Epidemiology Collaboration below 80 mL per minute at Screening.
24. Participants should refrain from consumption of any food containing poppy seeds within 48 hours prior to Screening and Day 1.
25. Participants should refrain from strenuous exercise (including weightlifting) within 96 hours prior to Screening and Day 1.
26. Any physical, psychological, mental and/or social reason which in the opinion of the Investigator makes the participant unsuitable for the study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central Randomisation
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer generated randomisation sequence in a 3:1 ratio, RES-010: Placebo.
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 1
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD

Funding & Sponsors
Funding source category [1] 321396 0
Commercial sector/Industry
Name [1] 321396 0
Resalis Therapeutics Australia Pty Ltd
Country [1] 321396 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Resalis Therapeutics Australia Pty Ltd
Address
Country
Australia
Secondary sponsor category [1] 324285 0
Commercial sector/Industry
Name [1] 324285 0
Accelagen Pty Ltd
Address [1] 324285 0
Country [1] 324285 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319936 0
Bellberry Human Research Ethics Committee A
Ethics committee address [1] 319936 0
Ethics committee country [1] 319936 0
Australia
Date submitted for ethics approval [1] 319936 0
18/03/2026
Approval date [1] 319936 0
30/04/2026
Ethics approval number [1] 319936 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148878 0
Dr Indika Leelasena
Address 148878 0
University of the Sunshine Coast Clinical Trials, Level 1 Health Hub Morayfield, 19-31 Dickson Road, Morayfield Queensland 4506
Country 148878 0
Australia
Phone 148878 0
+61 7 5456 3965
Fax 148878 0
Email 148878 0
Contact person for public queries
Name 148879 0
Alistair Mallard
Address 148879 0
Level 1 Health Hub Morayfield, 19-31 Dickson Road, Morayfield Queensland 4506
Country 148879 0
Australia
Phone 148879 0
+61 7 5409 8644
Fax 148879 0
Email 148879 0
Contact person for scientific queries
Name 148880 0
Dr Indika Leelasena
Address 148880 0
University of the Sunshine Coast Clinical Trials, Level 1 Health Hub Morayfield, 19-31 Dickson Road, Morayfield Queensland 4506
Country 148880 0
Australia
Phone 148880 0
+61 7 5456 3965
Fax 148880 0
Email 148880 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.